Trial · NCT07900165
Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer
NCT07900165, Phase 1, Phase 2, Not yet recruiting, CytomX Therapeutics
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer. Trials, record NCT07900165. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT07900165
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Varsetatug Masetecan in Combination With Anti-Cancer Therapies in Colorectal Cancer
- NCT number
- NCT07900165
- Status
- Not yet recruiting
- Phases
- Phase 1, Phase 2
- Enrollment
- 368 participants, estimated
- Lead sponsor
- CytomX Therapeutics
- Conditions
- Colo-rectal Cancer
- Interventions
- varsetatug masetecan, bevacizumab + 5-FU + leucovorin, bevacizumab
- First posted
- 2026-10-28
- Last updated
- 2026-10-28
Source ClinicalTrials.gov
Registered outcomes8
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Part 1 - Safety and tolerability of varsetatug masetecan in combination with bevacizumab + 5-FU + leucovorin | 27 months | The number of participants experiencing a dose-limiting toxicity (DLT) as defined in the protocol, AEs (adverse events), and treatment-emergent adverse events (TEAEs) at any dose level |
| Primary | Part 2 - Progression-free survival (PFS) based on blinded independent central review (BICR) | 27 months | PFS defined as the time from participant allocation to a trial intervention to the first documentation of objective disease progression, as determined by BICR according to Response Evaluation Criteria in Solid Tumors (RECIST) v1.1, or death due to any cause, whichever occurs first |
| Secondary | Objective Response Rate (ORR) | 27 months | ORR defined as the proportion of participants with a complete response (CR) or partial response (PR), as determined by BICR and Investigator assessment according to RECIST v1. |
| Secondary | Disease Control Rate (DCR) | 27 months | DCR defined as the proportion of participants with confirmed CR, PR, or stable disease (SD), as determined by BICR and Investigator assessment according to RECIST v1.1 |
| Secondary | PFS based on Investigator assessment | 27 months | PFS defined as the time from participant allocation to a trial intervention to the first documentation of objective disease progression, as determined by Investigator assessment according to RECIST v1.1, or death due to any cause, whichever occurs first |
| Secondary | Overall Survival (OS) | 27 months | OS defined as the time from participant allocation to a trial intervention to death due to any cause |
| Secondary | Duration of Response (DOR) | 27 months | DOR for participants with a confirmed CR or PR, is defined as the time from the first occurrence of a documented objective response to disease progression or death due to any cause (whichever occurs first), as determined by BICR and Investigator assessment according to RECIST v1.1 |
| Secondary | Duration of Disease Control (DODC) | 27 months | DODC for participants with a confirmed CR, PR, or SD, is defined as the time from the first occurrence of a documented CR, PR, or SD to disease progression or death due to any cause (whichever occurs first), as determined by BICR and Investigator assessment according to RECIST v1.1 |
Source ClinicalTrials.gov
Outcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT07900165
GET https://conductscience.org/api/trials/v1/NCT07900165/registered